97 related articles for article (PubMed ID: 25296725)
1. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
2. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Boni J; Abbas R; Leister C; Burns J; Jordan R; Hoffmann M; DeMaio W; Hug B
Cancer Chemother Pharmacol; 2009 Jul; 64(2):263-70. PubMed ID: 19015855
[TBL] [Abstract][Full Text] [Related]
3. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M
Invest New Drugs; 2016 Oct; 34(5):625-35. PubMed ID: 27350064
[TBL] [Abstract][Full Text] [Related]
5. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
6. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
7. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
8. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Calvo E; Braiteh F; Von Hoff D; McWilliams R; Becerra C; Galsky MD; Jameson G; Lin J; McKane S; Wickremsinhe ER; Hynes SM; Bence Lin A; Hurt K; Richards D
Oncology; 2016; 91(5):251-260. PubMed ID: 27598338
[TBL] [Abstract][Full Text] [Related]
10. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
[TBL] [Abstract][Full Text] [Related]
11. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
12. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
Weiss GJ; Donehower RC; Iyengar T; Ramanathan RK; Lewandowski K; Westin E; Hurt K; Hynes SM; Anthony SP; McKane S
Invest New Drugs; 2013 Feb; 31(1):136-44. PubMed ID: 22492020
[TBL] [Abstract][Full Text] [Related]
15. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Calvo E; Chen VJ; Marshall M; Ohnmacht U; Hynes SM; Kumm E; Diaz HB; Barnard D; Merzoug FF; Huber L; Kays L; Iversen P; Calles A; Voss B; Lin AB; Dickgreber N; Wehler T; Sebastian M
Invest New Drugs; 2014 Oct; 32(5):955-68. PubMed ID: 24942404
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
18. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Doi T; Yoshino T; Shitara K; Matsubara N; Fuse N; Naito Y; Uenaka K; Nakamura T; Hynes SM; Lin AB
Anticancer Drugs; 2015 Nov; 26(10):1043-53. PubMed ID: 26288133
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
Wickremsinhe ER; Hynes SM; Palmieri MD; Mitchell MI; Abraham TL; Rehmel JF; Chana E; Jost LM; Cassidy KC
Xenobiotica; 2014 Sep; 44(9):827-41. PubMed ID: 24666335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]